Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery

Alcon Research1 site in 1 country267 target enrollmentSeptember 2005

ConditionsCataract

DrugsNepafenac Ophthalmic Suspension, 0.1%

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Cataract
Sponsor: Alcon Research
Enrollment: 267
Locations: 1
Primary Endpoint: Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.

Registry

clinicaltrials.gov

Start Date

September 2005

End Date

March 2006

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Alcon Research

Eligibility Criteria

Inclusion Criteria

•planned cataract extraction with posterior chamber intraocular lens implantation

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).